liposarcoma

News

ASCO26: Verzenio gives hope of liposarcoma treatment advance

The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.

News

Boehringer moves liposarcoma drug into pivotal trial

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks